High Penicillin Prescribing Could Build Reservoirs of Resistance

This article originally appeared here.
Share this content:
High Penicillin Prescribing Could Build Reservoirs of Resistance
High Penicillin Prescribing Could Build Reservoirs of Resistance

(HealthDay News) -- High penicillin G prescribing may lead to an altered level of resistance in the commensal viridans group streptococci (VGS) population, which may be important in subsequent horizontal gene transfer events, according to a study published online Jan. 21 in the Journal of Clinical Pharmacy and Therapeutics.

Colin E. Goldsmith, M.B., B.Ch., from Belfast City Hospital in the United Kingdom, and colleagues examined the prescribing practices in general practice and their impact on antibiotic resistance. Sixty-five patients seen in general practice by high and low prescribers of oral antibiotics were enrolled in the study. VGS were collected from the nasal passages and oropharynx region of patients and tested for antibiotic resistance.

The researchers found that the minimum inhibitory concentrations did not differ significantly between high and low general practice prescribers with doxycycline (P = 0.094), erythromycin (P = 0.122), ofloxacin (P = 0.193), and levofloxacin (P = 0.058). With regard to penicillin, there was a significant difference between high and low general practice prescribers (P = 0.031).

"This finding is important as the β-lactams are the most commonly prescribed oral antibiotic in the community," the authors write. "High prescribing practices may lead to an altered (higher) level of resistance to these agents in the commensal VGS population, which may be important as reservoirs of antibiotic resistance determinants in subsequent horizontal gene transfer events, particularly with newly colonizing pathogens, including pneumococci."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths